The nomenclature FLJ20433 Activators implies a theoretical group of chemical compounds devised to enhance the activity of the protein encoded by the FLJ20433 gene. The FLJ acronym typically denotes full-length long Japan, a naming convention arising from a project aimed at discovering full-length long cDNA sequences in the Japanese population. Activators is purely speculative and does not correspond to any known chemical class. Should such a protein exist and be identified, activators would be molecules that interact with this protein to upregulate its function. These activators could potentially work by a variety of mechanisms, such as binding to the protein to stabilize its active form, increasing its expression through transcriptional regulation, or enhancing its interaction with other cellular components. The specific chemical properties of FLJ20433 Activators would depend significantly on the tertiary and quaternary structure of the FLJ20433 protein, as well as its role within the cellular machinery.
In the scenario of FLJ20433 Activators' development, the first step would be to ascertain the biological function of the FLJ20433 protein. This would likely entail a combination of genomic, proteomic, and bioinformatic techniques to map out the protein's structure, its domains of activity, and its cellular localization. Understanding the protein's role within the cell would be pivotal, and this could involve delving into its involvement in cellular processes, its interaction networks, and its regulation both at the genetic and post-translational levels. Once a comprehensive understanding of FLJ20433 is obtained, attention would turn to the chemical design of activators. These activators would be synthesized based on the structure of the protein and predicted interaction sites using computational chemistry and molecular modeling. The design process would also draw on knowledge from related proteins or homologous systems, where available. Subsequent experimental phases would involve in vitro and in vivo assays to test the compounds' efficacy in activating the FLJ20433 protein. These assays would measure not only the binding affinity and specificity of the activators but also their capacity to modulate the protein's activity in a controlled manner. Through this iterative process of hypothesis, design, synthesis, and testing, a class of FLJ20433 Activators could potentially be produced, offering insight into the biological function of the protein and serving as molecular probes for further scientific inquiry.
VOIR ÉGALEMENT...
Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
---|---|---|---|---|---|---|
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Cause des dommages à l'ADN en inhibant la ribonucléotide réductase, induisant potentiellement des enzymes de réparation de l'ADN, y compris EXD3. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Forme des adduits à l'ADN entraînant des dommages à l'ADN, ce qui peut entraîner une régulation à la hausse des protéines de réparation de l'ADN telles que EXD3. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Induit des ruptures de brins d'ADN en inhibant la topoisomérase II, ce qui pourrait renforcer l'expression des enzymes de réparation de l'ADN. | ||||||
Methyl methanesulfonate | 66-27-3 | sc-250376 sc-250376A | 5 g 25 g | $55.00 $130.00 | 2 | |
Agent alkylant causant des dommages à l'ADN, déclenchant potentiellement l'expression des voies de réparation de l'ADN, y compris EXD3. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Anthracycline qui s'intercale dans l'ADN, causant des dommages et induisant éventuellement des mécanismes de réparation de l'ADN. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Réticule l'ADN, entraînant une augmentation de l'activité de réparation de l'ADN qui pourrait inclure l'expression de l'EXD3. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Inhibe la topoisomérase I, provoquant des cassures de l'ADN et pouvant entraîner une régulation à la hausse des enzymes de réparation de l'ADN comme EXD3. | ||||||
Bleomycin | 11056-06-7 | sc-507293 | 5 mg | $270.00 | 5 | |
Induit le clivage de l'ADN, augmentant potentiellement l'expression des gènes impliqués dans la réparation de l'ADN, tels que EXD3. | ||||||
Benzo[a]pyrene | 50-32-8 | sc-257130 | 1 g | $439.00 | 4 | |
Hydrocarbure aromatique polycyclique qui forme des adduits à l'ADN, pouvant induire l'expression des gènes de réparation de l'ADN. | ||||||
Acrylamide Solution, 40% | 79-06-1 | sc-3721 | 1 L | $98.00 | ||
Peut former des adduits à l'ADN entraînant des dommages génomiques, ce qui peut entraîner une régulation à la hausse des mécanismes de réparation de l'ADN, y compris l'expression de l'EXD3. |